euro adhoc: MediGene AG / MediGene and Yamanouchi Conclude Marketing and Development Partnership For Anti-Cancer Drug Leuprogel® (New Name: Eligard®) (E)

Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement.

Martinsried - San Diego, January 14, 2004. The German-American biotechnology company MediGene AG (Frankfurt, Prime Standard: MDG) has concluded a partnership with the pharmaceuticals group Yamanouchi for the commercialization in Europe of the anti-cancer drug Eligard®, previously known as Leuprogel®. Yamanouchi, the second largest pharmaceuticals company in Europe in the field of urology, will take on pan-European promotion and sale of the drug for the treatment of prostate cancer. In return MediGene will receive successive milestone payments totaling up to EUR23.5 million including a signing fee of EUR4 million, as well as royalties on sales of Eligard®.

At the beginning of December 2003, the one-month sustained release product of Leuprogel® / Eligard® received marketing authorization for Germany. The three-months product is still undergoing approval procedure by the German regulatory authorities. In April 2001, MediGene had acquired the license for Leuprogel® / Eligard® from the US company Atrix Laboratories, Inc.

Contact:
MediGene AG, e-mail: investor@medigene.com, Fax: ++ 49 - 89 - 85 65 -2920
Julia Hofmann, Public Relations , Phone: ++ 49 - 89 - 85 65 - 3324 Dr. Michael Nettersheim, Investor Relations, Phone: ++ 49 - 89 - 85 65 - 2946

Further inquiry note:
Julia Hofmann
Tel.: +49 (0)89 8565 3324
E-Mail: j.hofmann@medigene.com
Tel: +49 (0)89 8565 2900
FAX: +49 (0)89 8565 2920
Email: investor@medigene.com

Emittent: MediGene AG Lochhamer Str. 11 DE-82152 Martinsried Tel: +49 (0)89 8565 2900 FAX: +49 (0)89 8565 2920 Email: investor@medigene.com WWW: www.medigene.de ISIN: DE0005020903 WKN: 502090

end of announcement euro adhoc

Indizes: CDAX, Prime All Share, Prime Standard, Technologie All Share
Börsen: regulated dealing Frankfurter Wertpapierbörse; free trade Niedersächsische Börse zu Hannover, Berliner Wertpapierbörse, Bayerische Börse, Hamburger Wertpapierbörse, Bremer Wertpapierbörse (BWB), Börse Düsseldorf, Baden-Württembergische Wertpapierbörse Branche: Biotechnology
Sprache: Englisch

OTS-ORIGINALTEXT UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS | OTB0007